Personalized Treatment of Patients With Primary Aldosteronism

Hiba Obeid, Stanley M. Chen Cardenas, Shafaq Khairi, Adina F. Turcu

Research output: Contribution to journalReview articlepeer-review


Primary aldosteronism (PA) is a highly prevalent yet underdiagnosed secondary cause of hypertension. PA is associated with increased cardiovascular and renal morbidity compared with patients with primary hypertension. Thus, prompt identification and targeted therapy of PA are essential to reduce cardiovascular and renal morbidity and mortality in a large population with hypertension. Unilateral adrenalectomy is preferred for lateralized PA as the only potentially curative therapy. Surgery also mitigates the risk of cardiovascular and renal complications associated with PA. Targeted medical therapy, commonly including a mineralocorticoid receptor antagonist, is offered to patients with bilateral PA and those who are not surgical candidates. Novel therapies, including nonsteroidal mineralocorticoid receptor antagonists and aldosterone synthase inhibitors, are being developed as alternative options for PA treatment. In this review article, we discuss how to best individualize therapy for patients with PA.

Original languageEnglish (US)
Pages (from-to)484-490
Number of pages7
JournalEndocrine Practice
Issue number6
StatePublished - Jun 2023


  • adrenal venous sampling
  • aldosterone
  • hypertension
  • mineralocorticoid receptor antagonist
  • primary aldosteronism
  • renin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Personalized Treatment of Patients With Primary Aldosteronism'. Together they form a unique fingerprint.

Cite this